2
|
Vandana, Kantipudi S, Maheshwari N, Sharma S, Sahni G. Cloning and purification of an anti-thrombotic, chimeric Staphylokinase in Pichia pastoris. Protein Expr Purif 2019; 162:1-8. [PMID: 31108209 DOI: 10.1016/j.pep.2019.05.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2018] [Revised: 04/17/2019] [Accepted: 05/16/2019] [Indexed: 10/26/2022]
Abstract
There has been an increasing prevalence of cardiovascular diseases such as myocardial infarction and stroke in modern societies because of multiple lifestyle related issues like sedentariness and obesity, alcohol consumption and many more "life-style"factors. The FDA-approved thrombolytics such as Tissue Plasminogen Activator, Streptokinase etc. are used to lyse the clots in thrombotic disorders such as myocardial infarction, stroke etc. but re-occlusion and bleeding that are co-incident to their clinical usage are not addressed. Hence, there is need to develop thrombolytics having properties like increased fibrin clot specificity and thrombin inhibition capability to prevent re-occlusion. In the present work, a fusion protein construct containing two components i.e. Staphylokinase (SAK) and Epidermal Growth Factor (EGF) 4, 5, 6-like domains of human thrombomodulin (THBD) was expressed in Pichia pastoris after genetic optimization. SAK isolated from Staphylococcus aureus is a fibrin-specific plasminogen activator while EGF 4, 5, 6-like domains are reported to be responsible for imparting thrombin inhibition to human thrombomodulin, and therefore, expected could help prevent re-occlusion in the novel construct - SAK_EGF, which is a 43 kDa protein. After expression, it was purified (approx. 13-fold) using two-step purification protocol involving ion-exchange followed by Gel Filtration Chromatography (GFC). The functional characterization including plasminogen activation and thrombin inhibition showed that both the fusion partners viz. SAK and 4,5,6 EGF-like domains retained their respective activities after fusion, confirming it to be a bio-active construct. Thus, this engineered protein could be clinically promising due to the combinatorial effect of fibrin-specific thrombus lysis and prevention of re-occulusion.
Collapse
Affiliation(s)
- Vandana
- Division of Protein Science and Engineering, CSIR-Institute of Microbial Technology, Sector39-A, Chandigarh, India
| | - Satish Kantipudi
- Division of Protein Science and Engineering, CSIR-Institute of Microbial Technology, Sector39-A, Chandigarh, India
| | - Neeraj Maheshwari
- Division of Protein Science and Engineering, CSIR-Institute of Microbial Technology, Sector39-A, Chandigarh, India
| | - Sheetal Sharma
- Division of Protein Science and Engineering, CSIR-Institute of Microbial Technology, Sector39-A, Chandigarh, India
| | - Girish Sahni
- Division of Protein Science and Engineering, CSIR-Institute of Microbial Technology, Sector39-A, Chandigarh, India.
| |
Collapse
|
3
|
Liu R, Zhao B, Zhang Y, Gu J, Yu M, Song H, Yu M, Mo W. High-level expression, purification, and enzymatic characterization of truncated human plasminogen (Lys531-Asn791) in the methylotrophic yeast Pichia pastoris. BMC Biotechnol 2015; 15:50. [PMID: 26054637 PMCID: PMC4460660 DOI: 10.1186/s12896-015-0179-z] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2015] [Accepted: 06/01/2015] [Indexed: 01/28/2023] Open
Abstract
Background Plasmin is a serine protease that plays a critical role in fibrinolysis, which is a process that prevents blood clots from growing and becoming problematic. Recombinant human microplasminogen (rhμPlg) is a derivative of plasmin that solely consists of the catalytic domain of human plasmin and lacks the five kringle domains found in the native protein. Developing an industrial production method that provides high yields of this protein with high purity, quality, and potency is critical for preclinical research. Results The human microplasminogen gene was cloned into the pPIC9K vector, and the recombinant plasmid was transformed into Pichia pastoris strain GS115. The concentration of plasmin reached 510.1 mg/L of culture medium. Under fermentation conditions, the yield of rhμPlg was 1.0 g/L. We purified rhμPlg to 96 % purity by gel-filtration and cation-exchange chromatography. The specific activity of rhμPlg reached 23.6 U/mg. The Km of substrate hydrolysis by recombinant human microplasmin was comparable to that of human plasmin, while rhμPlm had higher kcat/Km values than plasmin. The high purity and activity of the rhμPlg obtained here will likely prove to be a valuable tool for studies of its application in thrombotic diseases and vitreoretinopathies. Conclusions Reliable rhμPlg production (for use in therapeutic applications) is feasible using genetically modified P. pastoris as a host strain. The successful expression of rhμPlg in P. pastoris lays a solid foundation for its downstream application. Electronic supplementary material The online version of this article (doi:10.1186/s12896-015-0179-z) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Rongzeng Liu
- Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Fudan University, 138 Yixueyan Rd, Shanghai, 200032, China. .,Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, 138 Yixueyan Rd, Shanghai, 200032, China.
| | - Bing Zhao
- Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Fudan University, 138 Yixueyan Rd, Shanghai, 200032, China. .,Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, 138 Yixueyan Rd, Shanghai, 200032, China.
| | - Yanling Zhang
- Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Fudan University, 138 Yixueyan Rd, Shanghai, 200032, China. .,Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, 138 Yixueyan Rd, Shanghai, 200032, China.
| | - Junxiang Gu
- Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Fudan University, 138 Yixueyan Rd, Shanghai, 200032, China. .,Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, 138 Yixueyan Rd, Shanghai, 200032, China.
| | - Mingrong Yu
- Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Fudan University, 138 Yixueyan Rd, Shanghai, 200032, China. .,Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, 138 Yixueyan Rd, Shanghai, 200032, China.
| | - Houyan Song
- Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Fudan University, 138 Yixueyan Rd, Shanghai, 200032, China. .,Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, 138 Yixueyan Rd, Shanghai, 200032, China. .,Collaborative Innovation Center for Biotherapy, Sichuan University, Huaxi Campus: No.17 People's South Road, Chengdu, 610041, China.
| | - Min Yu
- Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Fudan University, 138 Yixueyan Rd, Shanghai, 200032, China. .,Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, 138 Yixueyan Rd, Shanghai, 200032, China.
| | - Wei Mo
- Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Fudan University, 138 Yixueyan Rd, Shanghai, 200032, China. .,Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, 138 Yixueyan Rd, Shanghai, 200032, China.
| |
Collapse
|